Skip to main content
University of California San Francisco
About UCSF
Search UCSF
UCSF Medical Center
Radiology
Search
About
People
Opportunity and Outreach
Wellbeing and Professional Climate
Make a Gift
Contact Us
Patient Care
For Health Professionals
For Patients
Services Offered
Clinical Divisions
Patient Safety
Education
Diagnostic Radiology Residency
Integrated IR Residency
Independent IR Residency
NucMed Residency & Fellowship
Fellowships
T32 Program
Medical Student Education
Master of Science in Biomedical Imaging (MSBI)
Continuing Medical Education
The Margulis Society for Alumni
Distinguished Lecture Series
Research
Research Directory
Imaging Research Symposium
Research Conference
UCSF Radiology at RSNA
Core Services
Academic Affairs
Academic Recruitment
Academic Advancement
Development & Courses
Faculty Mentoring
Faculty Thrive Guide
Celebrating Faculty & Alumni
Department Committees
FAQs
Locations
News
Events
Honors and Awards
Department Publications
Breadcrumb
Home
/
About
/
People
/
Rachel Nosheny, PhD
/
Publications
Rachel Nosheny, PhD's Publications
Classification of hoarding and comorbid neuropsychiatric symptoms.
Community-engaged efforts to increase retention of Black American online registry participants.
Correction: An Anti-β-Amyloid vaccine for treating cognitive deficits in a mouse model of down syndrome.
Evaluating the Accuracy of Web-Based and In-Clinic Subjective Cognitive Decline Assessments in Detecting Cognitive Impairment: Multicohort Study.
Lucid episodes among people with Alzheimer's disease and related dementias and their impact on family caregiver stress and grief (LEAD): protocol for a longitudinal observational study.
Mobile Toolbox sequences task: development and validation of a remote, smartphone-based working memory test.
Self- and Informant-Report Cognitive Decline Discordance and Mild Cognitive Impairment Diagnosis.
Subjective cognitive decline predicts longitudinal neuropsychological test performance in an unsupervised online setting in the Brain Health Registry.
Test taking location and practice effects as factors contributing to scores on remotely administered neurocognitive performance tests in a sample of older adults.
A Protocol for the Inclusion of Minoritized Persons in Alzheimer Disease Research From the ADNI3 Diversity Taskforce.
A short version of the Everyday Cognition scale can predict clinical progression and cognitive decline.
Development and Validation of a Vocabulary Measure in the Mobile Toolbox.
Development and validation of an episodic memory measure in the Mobile Toolbox (MTB): Arranging Pictures.
Development and Validation the Mobile Toolbox (MTB) Spelling Test.
Examining Demographic Factors, Psychosocial Wellbeing and Cardiovascular Health in Subjective Cognitive Decline in the Brain Health Registry Cohort.
Mobile toolbox (MTB) remote measures of executive function and processing speed: development and validation.
Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials.
Participant completion of longitudinal assessments in an online cognitive aging registry: The role of medical conditions.
Performance of a Short Version of the Everyday Cognition Scale (ECog-12) to Detect Cognitive Impairment.
Performance of Plasma Biomarkers Combined with Structural MRI to Identify Candidate Participants for Alzheimer's Disease-Modifying Therapy.
Remote olfactory assessment using the NIH Toolbox Odor Identification test and the brain health registry.
Storyteller in ADNI4: Application of an early Alzheimer's disease screening tool using brief, remote, and speech-based testing.
The ADNI Administrative Core: Ensuring ADNI's success and informing future AD clinical trials.
The ADNI4 Digital Study: A novel approach to recruitment, screening, and assessment of participants for AD clinical research.
The Alzheimer's Disease Neuroimaging Initiative-4 (ADNI-4) Engagement Core: A culturally informed, community-engaged research (CI-CER) model to advance brain health equity.
The effect of study partner characteristics on the reporting of neuropsychiatric symptoms across the neurocognitive spectrum.
Theory-Based Message Design for Recruitment of Underrepresented Racial/Ethnic Groups Into Alzheimer's-Focused Research Registries.
Unsupervised Online Paired Associates Learning Task from the Cambridge Neuropsychological Test Automated Battery (CANTAB®) in the Brain Health Registry.
Validity and reliability of the Mobile Toolbox Faces and Names memory test.
Associations between Participant Characteristics and Participant Feedback about an Unsupervised Online Cognitive Assessment in a Research Registry.
Brain Health Registry Study Partner Portal: Novel infrastructure for digital, dyadic data collection.
Brain health registry updates: An online longitudinal neuroscience platform.
Evaluation of the Electronic Clinical Dementia Rating for Dementia Screening.
How intention to join an Alzheimer's participant recruitment registry differs by race, ethnicity, sex, and family history: Results from a national survey of US adults.
Relationship of Hoarding and Depression Symptoms in Older Adults.
The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022.
The Community Engaged Digital Alzheimer's Research (CEDAR) Study: A Digital Intervention to Increase Research Participation of Black American Participants in the Brain Health Registry.
Understanding Online Registry Facilitators and Barriers Experienced by Black Brain Health Registry Participants: The Community Engaged Digital Alzheimer's Research (CEDAR) Study.
Association of Major Depressive Disorder with remotely administered measures of cognition and subjective report of cognitive difficulties across the adult age spectrum.
Clinical research in dementia: A perspective on implementing innovation.
Cognitive profile of people with mild behavioral impairment in Brain Health Registry participants.
Development and implementation of an electronic Clinical Dementia Rating and Financial Capacity Instrument-Short Form.
Digital culturally tailored marketing for enrolling Latino participants in a web-based registry: Baseline metrics from the Brain Health Registry.
Health-related quality of life in hoarding: A comparison to chronic conditions with high disease burden.
Hoarding symptoms are associated with higher rates of disability than other medical and psychiatric disorders across multiple domains of functioning.
Identifying psychiatric and neurological comorbidities associated with hoarding disorder through network analysis.
Improving generalizability and study design of Alzheimer's disease cohort studies in the United States by including under-represented populations.
Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a community-engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4.
Putting participants and study partners FIRST when clinical trials end early.
Remote blood collection from older adults in the Brain Health Registry for plasma biomarker and genetic analysis.
Screening and enrollment of underrepresented ethnocultural and educational populations in the Alzheimer's Disease Neuroimaging Initiative (ADNI).
Self-reporting of psychiatric illness in an online patient registry is a good indicator of the existence of psychiatric illness.
The Advisory Group on Risk Evidence Education for Dementia: Multidisciplinary and Open to All.
The role of dyadic cognitive report and subjective cognitive decline in early ADRD clinical research and trials: Current knowledge, gaps, and recommendations.
Unsupervised Performance of the CogState Brief Battery in the Brain Health Registry: Implications for Detecting Cognitive Decline.
Validity of Online Versus In-Clinic Self-Reported Everyday Cognition Scale.
Web-Based Mindfulness-Based Interventions for Well-being: Randomized Comparative Effectiveness Trial.
Brain health registry GenePool study: A novel approach to online genetics research.
Machine learning approaches to predicting amyloid status using data from an online research and recruitment registry: The Brain Health Registry.
Poor Sleep Quality and Daytime Fatigue Are Associated With Subjective but Not Objective Cognitive Functioning in Clinically Relevant Hoarding.
Reliability and Validity of a Home-Based Self-Administered Computerized Test of Learning and Memory Using Speech Recognition.
rPOP: Robust PET-only processing of community acquired heterogeneous amyloid-PET data.
The search for a convenient procedure to detect one of the earliest signs of Alzheimer's disease: A systematic review of the prediction of brain amyloid status.
Effects of sex, race, ethnicity, and education on online aging research participation.
Hoarding disorder is associated with self-reported cardiovascular / metabolic dysfunction, chronic pain, and sleep apnea.
Internet-based hoarding assessment: The reliability and predictive validity of the internet-based Hoarding Rating Scale, Self-Report.
Item response theory analysis of the Clinical Dementia Rating.
Late contributions of repetitive head impacts and TBI to depression symptoms and cognition.
Predicting amyloid status using self-report information from an online research and recruitment registry: The Brain Health Registry.
Validation of online functional measures in cognitively impaired older adults.
Associations among amyloid status, age, and longitudinal regional brain atrophy in cognitively unimpaired older adults.
Cognitive Performance in Parkinson's Disease in the Brain Health Registry.
Study partner-reported decline identifies cognitive decline and dementia risk.
Online study partner-reported cognitive decline in the Brain Health Registry.
The Brain Health Registry: An internet-based platform for recruitment, assessment, and longitudinal monitoring of participants for neuroscience studies.
Total Sleep Time Interacts With Age to Predict Cognitive Performance Among Adults.
Unsupervised online neuropsychological test performance for individuals with mild cognitive impairment and dementia: Results from the Brain Health Registry.
Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology.
An Anti-β-Amyloid Vaccine for Treating Cognitive Deficits in a Mouse Model of Down Syndrome.
Assessing risk for preclinical β-amyloid pathology with APOE, cognitive, and demographic information.
Registries and Cohorts to Accelerate Early Phase Alzheimer's Trials. A Report from the E.U./U.S. Clinical Trials in Alzheimer's Disease Task Force.
Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease.
Increased cortical synaptic activation of TrkB and downstream signaling markers in a mouse model of Down Syndrome.
Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2.
Emerging β-amyloid pathology and accelerated cortical atrophy.
Variables associated with hippocampal atrophy rate in normal aging and mild cognitive impairment.
CSF protein biomarkers predicting longitudinal reduction of CSF β-amyloid42 in cognitively healthy elders.
Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults.
Formoterol, a long-acting β2 adrenergic agonist, improves cognitive function and promotes dendritic complexity in a mouse model of Down syndrome.
Increased efficiency of the GABAA and GABAB receptor-mediated neurotransmission in the Ts65Dn mouse model of Down syndrome.
Chronic unpredictable stress promotes neuronal apoptosis in the cerebral cortex.
Brain-derived neurotrophic factor expression in the substantia nigra does not change after lesions of dopaminergic neurons.
Brain-derived neurotrophic factor prevents human immunodeficiency virus type 1 protein gp120 neurotoxicity in the rat nigrostriatal system.
Brain-derived neurotrophic factor prevents the nigrostriatal degeneration induced by human immunodeficiency virus-1 glycoprotein 120 in vivo.
Axonal transport of human immunodeficiency virus type 1 envelope protein glycoprotein 120 is found in association with neuronal apoptosis.
Intrastriatal administration of human immunodeficiency virus-1 glycoprotein 120 reduces glial cell-line derived neurotrophic factor levels and causes apoptosis in the substantia nigra.
Brain-derived neurotrophic factor as a prototype neuroprotective factor against HIV-1-associated neuronal degeneration.
Human immunodeficiency virus type 1 glycoprotein gp120 reduces the levels of brain-derived neurotrophic factor in vivo: potential implication for neuronal cell death.
Human immunodeficiency virus type 1 protein gp120 causes neuronal cell death in the rat brain by activating caspases.
Plasma membrane expression of heat shock protein 60 in vivo in response to infection.
